脉血康肠溶片在治疗急性脑出血患者水肿、促进脑血肿吸收中的作用

Clinical efficacy of Maixuekang in treating acute cerebral hemorrhage hematomas and promoting brain hemorrhage

目的:研究脉血康在治疗急性脑出血和促进脑血肿吸收中的临床疗效。方法:选择2013年4月~2015年l 2月我院收治的192例急性期脑出血患者,在入院后立即行脑CT、血常规、凝血功能检查等确诊,随机分成对照组、观察组两组,两组均进行抗感染、甘露醇等常规治疗,观察组在此基础上加用脉血康肠溶片进行治疗,对比两组疗效和治疗各阶段脑水肿体积、NIHSS评分情况。结果:治疗前两组水肿体积、NIHSS评分均无统计学差异(P>0.05)。治疗14、28d后观察组水肿体积[(15.33±4.42)、(9.51±3.87)cm^2]与对照组[(18.12±4.38)、(13.28±4.35)cm^2]差异具有统计学意义(P<0.01);治疗14、28d后观察组NIHSS评分[(18.73±4.65)、(14.25±4.30)]与对照组[(22.01±4.42)、(20.33±3.97)]差异具有统计学意义(P<0.01);治疗28d后观察组总有效率为68.75%,高于对照组(53.12%)(P<0.01)。讨论:脉血康肠溶片作为一种凝血酶抑制剂,可以有效减轻急性脑出血后局部凝血酶含量变化导致的一系列病理学改变,促进血肿吸收和神经功能恢复,同时副作用小、安全性高,值得临床推广。

Objective： To study the clinical efficacy of Maixuekang in treating acute cerebral hemorrhage hematomas and promoting brain hemorrhage. Methods： A total of 192 cases of patients treated within 3 h with acute intracerebral hemorrhage in our hospital during April 2013 to December 2015 were chosen, and after admission, brain CT, blood, coagulation function tests were immediately applied to them to make confirmation. They were randomly divided into two groups, control group and observation group. Both groups received anti-infective, Mannitol and other conventional treatment. Observation group were treated with enteric-coated tablets Maixuekang on this basis. The clinical efficacy of two groups and the various stages of treat- ment of cerebral hematoma volume and brain edema volume, NIHSS score were compared to perform statistical analysis. Re- suits： Before treatment, edema volume and HIHSS scores were not significantly different （P〉0.05）. Fourteen days and 28 d post-treatment observation group edema volume were （15.33±4.42） cm2 and （9.51±3.87） cm2 , the control group were （18.12 ±4.38） cm2 and （13.28±4.35） cm2 , respectively, the difference was statistically significant （P〈0.01） ; 14 d and 28 d after treatment NIHSS score of observation group were 18.73 ± 4.65 and 14.25± 4.30, the control group were 22.01± 4.42and 20.33 ±3.97, respectively, the difference was statistically significant （P〈0.01） ; 28 d after treatment observation group total effec- tive rate was 68.75 %, significantly higher than 53.12 % of the control group （P 〈0.01）. Conclusions.. Maixuekang enteric-coa-ted tablets as a thrombin inhibitor, can effectively reduce a series of pathological changes after acute cerebral hemorrhage caused by partial thrombin content, promote absorption of hematoma and neurological recovery, while the side effects is small, safe and worthy of promotion.